Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
- Conditions
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT04899921
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
FLX475 in Combination With Ipilimumab in Advanced Melanoma
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04894994
- Locations
- 🇺🇸
Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- SQZ Biotechnologies
- Target Recruit Count
- 5
- Registration Number
- NCT04892043
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04887870
- Locations
- 🇺🇸
Local Institution - 516-014-004, Columbus, Ohio, United States
🇺🇸Local Institution - 516-014-011, Albany, New York, United States
🇺🇸Local Institution - 516-014-027, Fairfax, Virginia, United States
A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT04868760
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, China
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 46
- Registration Number
- NCT04863885
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 55
- Registration Number
- NCT04855929
- Locations
- 🇪🇸
Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain
🇨🇭University Hospital Basel, Basel, Switzerland
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT04840615
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT04840589
- Locations
- 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸Montefiore Medical Center-Einstein Campus, Bronx, New York, United States
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 27
- Registration Number
- NCT04823403
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.